Literature DB >> 27748758

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.

D-L Qi1,2, D Cobrinik1,2,3,4,5,6.   

Abstract

Retinoblastomas can arise from cone photoreceptor precursors in response to the loss of pRB function. Cone precursor-specific circuitry cooperates with pRB loss to initiate this process and subsequently contributes to the malignancy. Intrinsic high-level MDM2 expression is a key component of the cone precursor circuitry and is thought to inactivate p53-mediated tumor surveillance, which could otherwise be induced in response to pRB loss. However, the MDM2-related MDM4 has also been proposed to abrogate p53-mediated tumor surveillance in the absence of detectable MDM2 in retinoblastoma cells, bringing into question the importance of high-level MDM2 versus MDM4 expression. Here we report that high-level MDM2 but not MDM4 has a consistent critical role in retinoblastoma cell proliferation in vitro, as well as in orthotopic xenografts. Reduction of either MDM2 or MDM4 weakly induced p53, yet reduction of MDM2 but not MDM4 severely impaired proliferation and survival through a p53-independent mechanism. Specifically, MDM2 upregulated the mRNA expression and translation of another component of the cone circuitry, MYCN, in retinoblastoma cells. Moreover, MYCN was essential to retinoblastoma cell growth and tumor formation, and ectopic MYCN partially reversed the effects of MDM2 depletion, indicating that MYCN is an important MDM2 target. These findings indicate that high-level MDM2 expression is needed in order to perform a critical p53-independent function and may obviate the need for genomic alterations to the p53 pathway during retinoblastoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748758      PMCID: PMC5374018          DOI: 10.1038/onc.2016.350

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

2.  Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.

Authors:  David Cobrinik; Irina Ostrovnaya; Maryam Hassimi; Satish K Tickoo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Genes Chromosomes Cancer       Date:  2013-10-10       Impact factor: 5.006

3.  p14ARF links the tumour suppressors RB and p53.

Authors:  S Bates; A C Phillips; P A Clark; F Stott; G Peters; R L Ludwig; K H Vousden
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

4.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

5.  Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation.

Authors:  Nieves Embade; David Fernández-Ramos; Marta Varela-Rey; Naiara Beraza; Marcella Sini; Virginia Gutiérrez de Juan; Ashwin Woodhoo; Nuria Martínez-López; Begoña Rodríguez-Iruretagoyena; Francisco Javier Bustamante; Ana Belén de la Hoz; Arkaitz Carracedo; Dimitris P Xirodimas; Manuel S Rodríguez; Shelly C Lu; José M Mato; María L Martínez-Chantar
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

Review 6.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

Review 7.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

8.  Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.

Authors:  Aaron Aslanian; Phillip J Iaquinta; Raluca Verona; Jacqueline A Lees
Journal:  Genes Dev       Date:  2004-06-02       Impact factor: 11.361

9.  Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53.

Authors:  D Sohn; V Graupner; D Neise; F Essmann; K Schulze-Osthoff; R U Jänicke
Journal:  Cell Death Differ       Date:  2009-02-20       Impact factor: 15.828

10.  Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells.

Authors:  David Cobrinik; Richard O Francis; David H Abramson; Thomas C Lee
Journal:  Mol Cancer       Date:  2006-12-12       Impact factor: 27.401

View more
  15 in total

1.  Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors.

Authors:  Hardeep P Singh; Sijia Wang; Kevin Stachelek; Sunhye Lee; Mark W Reid; Matthew E Thornton; Cheryl Mae Craft; Brendan H Grubbs; David Cobrinik
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-13       Impact factor: 11.205

Review 2.  Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer.

Authors:  Michelle G Zhang; John Y Lee; Ryan A Gallo; Wensi Tao; David Tse; Ravi Doddapaneni; Daniel Pelaez
Journal:  Pharmacol Res       Date:  2017-12-02       Impact factor: 7.658

3.  Shikonin-mediated up-regulation of miR-34a and miR-202 inhibits retinoblastoma proliferation.

Authors:  Yan Su; Shiyou Lu; Jincun Li; Liya Deng
Journal:  Toxicol Res (Camb)       Date:  2018-06-06       Impact factor: 3.524

4.  An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc-initiated retinoblastoma.

Authors:  Hardeep P Singh; Dominic W H Shayler; G Esteban Fernandez; Matthew E Thornton; Cheryl Mae Craft; Brendan H Grubbs; David Cobrinik
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

5.  A novel thyroid hormone receptor isoform, TRβ2-46, promotes SKP2 expression and retinoblastoma cell proliferation.

Authors:  Zhengke Li; Dong-Lai Qi; Hardeep P Singh; Yue Zou; Binghui Shen; David Cobrinik
Journal:  J Biol Chem       Date:  2019-01-14       Impact factor: 5.157

Review 6.  The MYCN Protein in Health and Disease.

Authors:  María Victoria Ruiz-Pérez; Aine Brigette Henley; Marie Arsenian-Henriksson
Journal:  Genes (Basel)       Date:  2017-03-30       Impact factor: 4.096

7.  HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.

Authors:  Dong Yang; Daomei Cheng; Qiu Tu; Huihui Yang; Bin Sun; Lanzhen Yan; Hongjuan Dai; Jierong Luo; Bingyu Mao; Yi Cao; Xiaoping Yu; Hua Jiang; Xudong Zhao
Journal:  Theranostics       Date:  2018-06-06       Impact factor: 11.556

8.  Functional genomics identifies new synergistic therapies for retinoblastoma.

Authors:  Arthur Aubry; Joel D Pearson; Katherine Huang; Izhar Livne-Bar; Mohammad Ahmad; Madhavan Jagadeesan; Vikas Khetan; Troy Ketela; Kevin R Brown; Tao Yu; Suying Lu; Jeffrey L Wrana; Jason Moffat; Rod Bremner
Journal:  Oncogene       Date:  2020-06-22       Impact factor: 9.867

9.  UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4.

Authors:  Heng He; Chunsik Lee; Jong Kyong Kim
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

10.  RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development.

Authors:  Sailaja V Elchuri; Swetha Rajasekaran; Wayne O Miles
Journal:  Front Genet       Date:  2018-05-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.